Skip to contentL
Lyell Immunopharma, Inc.
L
LYELLyell Immunopharma, Inc. Q1 2025 · 10-Q
Revenue$7.00K$7.00K+133.3% vs Q1 2024 Net Income-$52.20M-$52.20MN/M vs Q1 2024 EPS Diluted-$3.54-$3.54N/M vs Q1 2024 Operating Income-$57,367,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lyell Immunopharma, Inc. · CIK 1806952 · Engraved from SEC EDGAR
Free Cash Flowderived-$54,984,000N/M Margins · derivedOperating margin-819528.6%+1032971.4 pt vs Q1 2024
Net margin-745642.9%+1276590.5 pt vs Q1 2024
ended Mar 31, 2025 · filed May 13, 2025 · 43 d after period end